E Brignardello1, F Felicetti2, A Castiglione3, A Nervo2, E Biasin4, G Ciccone3, F Fagioli4, A Corrias5. 1. Transition Unit for Childhood Cancer Survivors, Città della Salute e della Scienza Hospital , Via Cherasco, 15, 10126, Turin, Italy. ebrignardello@cittadellasalute.to.it. 2. Transition Unit for Childhood Cancer Survivors, Città della Salute e della Scienza Hospital , Via Cherasco, 15, 10126, Turin, Italy. 3. Unit of Clinical Epidemiology, Città della Salute e della Scienza Hospital, University of Turin and Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy. 4. Pediatric Onco-Hematology, Città della Salute e della Scienza Hospital, Turin, Italy. 5. Pediatric Endocrinology Unit, Città della Salute e della Scienza Hospital, Turin, Italy.
Abstract
PURPOSE: To evaluate the prevalence of gonadal dysfunction and the associated risk factors in a cohort of male childhood cancer survivors (CCS). METHODS: Gonadal function was evaluated measuring FSH, LH, inhibin B and total testosterone levels. Patients with total testosterone <3 ng/dl were considered to have hypogonadism. Patients with FSH >10 UI/l and inhibin B <100 pg/ml were considered to have spermatogenesis damage (SD). To assess the impact of risk factors, we estimated crude and adjusted OR performing logistic regression models. RESULTS: One hundred and ninety-nine male CCS were enrolled; the median follow-up time was 14.01 years. SD was diagnosed in 68 patients, 16 CCS had primary hypogonadism, and 13 had central hypogonadism. The prevalence of gonadal dysfunction (SD or primary hypogonadism) was 45 %, similar in the three considered periods of pediatric cancer diagnosis (1985-1989, 1990-1999, >2000). The adjusted risk of gonadal dysfunction was higher in patients treated with radiotherapy (OR = 8.72; 95 % CI 3.94-19.30) and in those exposed to both alkylating and platinum-derived agents (OR = 9.22; 95 % CI 2.17-39.23). Sarcomas were the cancer diagnosis associated with the higher risk of gonadal dysfunction (OR = 3.69; 95 % CI 1.11-12.22). An extremely high rate of gonadal dysfunction was detected in patients who underwent hematopoietic stem cell transplantation and/or total body irradiation. CONCLUSIONS: Gonadal dysfunction still remains a significant late effect of anticancer therapies; thus, it is mandatory to inform patients (and parents) about this risk, and semen cryopreservation should be offered to all boys who are able to produce semen.
PURPOSE: To evaluate the prevalence of gonadal dysfunction and the associated risk factors in a cohort of male childhood cancer survivors (CCS). METHODS: Gonadal function was evaluated measuring FSH, LH, inhibin B and total testosterone levels. Patients with total testosterone <3 ng/dl were considered to have hypogonadism. Patients with FSH >10 UI/l and inhibin B <100 pg/ml were considered to have spermatogenesis damage (SD). To assess the impact of risk factors, we estimated crude and adjusted OR performing logistic regression models. RESULTS: One hundred and ninety-nine male CCS were enrolled; the median follow-up time was 14.01 years. SD was diagnosed in 68 patients, 16 CCS had primary hypogonadism, and 13 had central hypogonadism. The prevalence of gonadal dysfunction (SD or primary hypogonadism) was 45 %, similar in the three considered periods of pediatric cancer diagnosis (1985-1989, 1990-1999, >2000). The adjusted risk of gonadal dysfunction was higher in patients treated with radiotherapy (OR = 8.72; 95 % CI 3.94-19.30) and in those exposed to both alkylating and platinum-derived agents (OR = 9.22; 95 % CI 2.17-39.23). Sarcomas were the cancer diagnosis associated with the higher risk of gonadal dysfunction (OR = 3.69; 95 % CI 1.11-12.22). An extremely high rate of gonadal dysfunction was detected in patients who underwent hematopoietic stem cell transplantation and/or total body irradiation. CONCLUSIONS:Gonadal dysfunction still remains a significant late effect of anticancer therapies; thus, it is mandatory to inform patients (and parents) about this risk, and semen cryopreservation should be offered to all boys who are able to produce semen.
Entities:
Keywords:
Childhood cancer survivors; Gonadal function; Late effects; Male infertility
Authors: Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10 Impact factor: 4.254
Authors: S Joshi; B N Savani; E J Chow; M H Gilleece; J Halter; D A Jacobsohn; J Pidala; G P Quinn; J-Y Cahn; A A Jakubowski; N R Kamani; H M Lazarus; J D Rizzo; H C Schouten; G Socie; P Stratton; M L Sorror; A B Warwick; J R Wingard; A W Loren; N S Majhail Journal: Bone Marrow Transplant Date: 2014-01-13 Impact factor: 5.483
Authors: E Brignardello; F Felicetti; A Castiglione; P Chiabotto; A Corrias; F Fagioli; G Ciccone; G Boccuzzi Journal: Eur J Endocrinol Date: 2013-02-20 Impact factor: 6.664
Authors: P Anserini; S Chiodi; S Spinelli; M Costa; N Conte; F Copello; A Bacigalupo Journal: Bone Marrow Transplant Date: 2002-10 Impact factor: 5.483
Authors: Christine Wyns; Mara Curaba; Bernard Vanabelle; Anne Van Langendonckt; Jacques Donnez Journal: Hum Reprod Update Date: 2010-01-04 Impact factor: 15.610
Authors: Wassim Chemaitilly; Qi Liu; Laura van Iersel; Kirsten K Ness; Zhenghong Li; Carmen L Wilson; Tara M Brinkman; James L Klosky; Nicole Barnes; Karen L Clark; Rebecca M Howell; Susan A Smith; Matthew J Krasin; Monika L Metzger; Gregory T Armstrong; Michael W Bishop; Hanneke M van Santen; Ching-Hon Pui; Deo Kumar Srivastava; Yutaka Yasui; Melissa M Hudson; Leslie L Robison; Daniel M Green; Charles A Sklar Journal: J Clin Oncol Date: 2019-09-26 Impact factor: 44.544
Authors: Natasha N Frederick; Vicky Lehmann; Astrid Ahler; Kristen Carpenter; Brooke Cherven; James L Klosky; Leena Nahata; Gwendolyn P Quinn Journal: Pediatr Blood Cancer Date: 2021-12-06 Impact factor: 3.838
Authors: Hanneke M van Santen; Marry M van den Heuvel-Eibrink; Marianne D van de Wetering; W Hamish Wallace Journal: Horm Res Paediatr Date: 2019-01-31 Impact factor: 2.852
Authors: F Cargnelutti; A Di Nisio; F Pallotti; M Spaziani; M G Tarsitano; D Paoli; C Foresta Journal: J Endocrinol Invest Date: 2022-03-14 Impact factor: 5.467
Authors: Vincenzo De Sanctis; Ashraf T Soliman; Mohamed A Yassin; Salvatore Di Maio; Giuseppe Millimaggi; Christos Kattamis Journal: Acta Biomed Date: 2018-04-03